Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Holds FDA Type C Meeting On Phase 3 Mino-Lok® Pathway for Approval
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 25, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.
Brand Name : Revyve
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2024
Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Study Phase : Approved
Sponsor : Qatar Datamation Systems
Deal Size : Undisclosed
Deal Type : Agreement
Kane Biotech Signs Deal with Qatar Datamation For Wound Gel Distribution
Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.
Brand Name : Revyve
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 28, 2024
Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Sponsor : Qatar Datamation Systems
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Study Phase : Approved
Sponsor : NRC IRAP
Deal Size : $0.2 million
Deal Type : Funding
Kane Biotech Receives Funding Support to Expand the Revyve Antimicrobial Wound Gel Family
Details : The funding will support the development of three additional products to build on Kane Biotech’s revyve Antimicrobial Wound Gel technology for management of ulcers.
Brand Name : Revye
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 13, 2024
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Sponsor : NRC IRAP
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kane Biotech Receives FDA Approval to Increase Dosage of Revyve™ Wound Gel
Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.
Brand Name : Revye
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 23, 2024
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharma Hits Key Goals in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Completes Enrollment In Pivotal Phase 3 Trial Of Mino-Lok To Salvage Catheters
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult po...
Brand Name : Revye
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2023
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Venus Remedies Expands Reach with the Launch of Elores in Ecuador
Details : Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Brand Name : Elores
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2023
Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
Details : Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?